Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zinnia P Parra-Guillen

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Clinical Pharmacokinetics|August 1, 2025
Role of Antidrug Antibodies in Oncolytic Viral Therapy: A Dynamic Modelling Approach in Cancer Patients Treated with V937 Alone or in CombinationZinnia P Parra-Guillen, Iñaki F Trocóniz, Tomoko Freshwater
Clinical Pharmacokinetics|December 18, 2014
Pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of monoclonal antibodies in childrenHelena Edlund, Johanna Melin, Zinnia P Parra-Guillen, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 13, 2013
Modeling tumor response after combined administration of different immune-stimulatory agentsZinnia P Parra-Guillen, Pedro Berraondo, Benjamin Ribba, et al.
Clinical Pharmacology and Therapeutics|July 22, 2024
Disentangling Anti-Tumor Response of Immunotherapy Combinations: A Physiologically Based Framework for V937 Oncolytic Virus and PembrolizumabAymara Sancho-Araiz, Zinnia P Parra-Guillen, Iñaki F Troconiz, et al.
Frontiers in Pharmacology|September 29, 2023
A physiologically based pharmacokinetic model for V937 oncolytic virus in miceSara Peribañez-Dominguez, Zinnia P Parra-Guillen, Tomoko Freshwater, et al.
Clinical Pharmacology and Therapeutics|September 29, 2019
Model-Informed Dose Selection for Xentuzumab, a Dual Insulin-Like Growth Factor-I/II-Neutralizing AntibodyZinnia P Parra-Guillen, Ulrike Schmid, Alvaro Janda, et al.
Frontiers in Immunology|February 3, 2025
Mechanistic PKPD modeling to describe cytokine release associated with CD3 T-cell engager therapiesApolline Lefèvre, Zinnia P Parra-Guillen, Iñaki F Trocóniz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2018
The Long Neglected Player: Modeling Tumor Uptake to Guide Optimal DosingLeire Ruiz-Cerdá, Eduardo Asín-Prieto, Zinnia P Parra-Guillen, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 12, 2019
A Quantitative Systems Pharmacology Model for the Key Interleukins Involved in Crohn's DiseaseVioleta Balbas-Martinez, Eduardo Asin-Prieto, Zinnia P Parra-Guillen, et al.
The AAPS Journal|November 18, 2025
Leveraging in vitro Tumor Cell Killing and Cytokine Release to Predict Cytokine Release Syndrome Associated with CD3 T-cell Bispecifics in Oncology: a Retrospective AnalysisApolline Lefèvre, Zinnia P Parra-Guillen, Iñaki F Trocóniz, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Clinical Pharmacokinetics|August 1, 2025
Role of Antidrug Antibodies in Oncolytic Viral Therapy: A Dynamic Modelling Approach in Cancer Patients Treated with V937 Alone or in CombinationZinnia P Parra-Guillen, Iñaki F Trocóniz, Tomoko Freshwater
Clinical Pharmacokinetics|December 18, 2014
Pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of monoclonal antibodies in childrenHelena Edlund, Johanna Melin, Zinnia P Parra-Guillen, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 13, 2013
Modeling tumor response after combined administration of different immune-stimulatory agentsZinnia P Parra-Guillen, Pedro Berraondo, Benjamin Ribba, et al.
Clinical Pharmacology and Therapeutics|July 22, 2024
Disentangling Anti-Tumor Response of Immunotherapy Combinations: A Physiologically Based Framework for V937 Oncolytic Virus and PembrolizumabAymara Sancho-Araiz, Zinnia P Parra-Guillen, Iñaki F Troconiz, et al.
Frontiers in Pharmacology|September 29, 2023
A physiologically based pharmacokinetic model for V937 oncolytic virus in miceSara Peribañez-Dominguez, Zinnia P Parra-Guillen, Tomoko Freshwater, et al.
Clinical Pharmacology and Therapeutics|September 29, 2019
Model-Informed Dose Selection for Xentuzumab, a Dual Insulin-Like Growth Factor-I/II-Neutralizing AntibodyZinnia P Parra-Guillen, Ulrike Schmid, Alvaro Janda, et al.
Frontiers in Immunology|February 3, 2025
Mechanistic PKPD modeling to describe cytokine release associated with CD3 T-cell engager therapiesApolline Lefèvre, Zinnia P Parra-Guillen, Iñaki F Trocóniz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2018
The Long Neglected Player: Modeling Tumor Uptake to Guide Optimal DosingLeire Ruiz-Cerdá, Eduardo Asín-Prieto, Zinnia P Parra-Guillen, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 12, 2019
A Quantitative Systems Pharmacology Model for the Key Interleukins Involved in Crohn's DiseaseVioleta Balbas-Martinez, Eduardo Asin-Prieto, Zinnia P Parra-Guillen, et al.
The AAPS Journal|November 18, 2025
Leveraging in vitro Tumor Cell Killing and Cytokine Release to Predict Cytokine Release Syndrome Associated with CD3 T-cell Bispecifics in Oncology: a Retrospective AnalysisApolline Lefèvre, Zinnia P Parra-Guillen, Iñaki F Trocóniz, et al.
Pageof 4